^
Association details:
Biomarker:MAP2K2 mutation
Cancer:Melanoma
Drug:Tafinlar (dabrafenib) (BRAF inhibitor)
Direction:Resistant
Evidence:
Evidence Level:
Resistant: D – Preclinical
New
Title:

The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma

Excerpt:
Compared to the effects of wild type MEK2, cells expressing resistance-associated MEK2 mutations were less sensitive to both RAF (dabrafenib; Fig. 2C) and MEK (trametinib; Fig. 2D) inhibition.
DOI:
10.1158/2159-8290.CD-13-0617